Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Adolescent
Adult
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Bendamustine Hydrochloride
Cohort Studies
Humans
Lenalidomide
/ administration & dosage
Lymphoma, Large B-Cell, Diffuse
/ pathology
Oxaliplatin
/ therapeutic use
Retrospective Studies
Rituximab
/ administration & dosage
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 09 2022
15 09 2022
Historique:
received:
11
10
2021
revised:
07
01
2022
accepted:
16
05
2022
pubmed:
9
6
2022
medline:
17
9
2022
entrez:
8
6
2022
Statut:
ppublish
Résumé
In RE-MIND2 (NCT04697160), patient-level outcomes from the L-MIND study (NCT02399085) of tafasitamab plus lenalidomide were retrospectively compared with patient-level matched observational cohorts treated with National Cancer Care Network (NCCN)/European Society for Medical Oncology (ESMO)-listed systemic therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Data were collected from health records of eligible patients aged ≥18 years with histologically confirmed DLBCL who had received ≥2 systemic therapies for DLBCL (including ≥1 anti-CD20 therapy). Patients from L-MIND were matched with patients from the RE-MIND2 observational cohort using estimated propensity score-based 1:1 nearest-neighbor matching, balanced for nine covariates. The primary analysis compared tafasitamab plus lenalidomide with patients who received any systemic therapy for R/R DLBCL (pooled in one cohort) or bendamustine plus rituximab (BR) or rituximab plus gemcitabine and oxaliplatin (R-GemOx; as two distinct cohorts). The primary endpoint was overall survival (OS). Secondary endpoints included treatment response and time-to-event outcomes. In RE-MIND2, 3,454 patients were enrolled from 200 sites in North America, Europe, and Asia-Pacific. Strictly matched pairs of patients consisted of tafasitamab plus lenalidomide versus systemic therapies pooled (n = 76 pairs), versus BR (n = 75 pairs), and versus R-GemOx (n = 74 pairs). Significantly prolonged OS was reported with tafasitamab plus lenalidomide versus systemic pooled therapies [hazard ratios (HR): 0.55; P = 0.0068], BR (HR: 0.42; P < 0.0001), and R-GemOx (HR: 0.47; P = 0.0003). RE-MIND2, a retrospective observational study, met its primary endpoint, demonstrating prolonged OS with tafasitamab plus lenalidomide versus BR and R-GemOx. See related commentary by Cherng and Westin, p. 3908.
Identifiants
pubmed: 35674661
pii: 704803
doi: 10.1158/1078-0432.CCR-21-3648
pmc: PMC9475241
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Oxaliplatin
04ZR38536J
Rituximab
4F4X42SYQ6
Bendamustine Hydrochloride
981Y8SX18M
Lenalidomide
F0P408N6V4
tafasitamab
QQA9MLH692
Banques de données
ClinicalTrials.gov
['NCT02399085', 'NCT04697160']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4003-4017Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
J Med Econ. 2020 Dec;23(12):1618-1622
pubmed: 33081555
J Clin Oncol. 2012 Dec 1;30(34):4243-8
pubmed: 23071233
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
Clin Pharmacol Ther. 2007 Aug;82(2):143-56
pubmed: 17554243
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):2-10
pubmed: 26537534
J Clin Oncol. 2010 Sep 20;28(27):4184-90
pubmed: 20660832
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Ann Hematol. 2014 Mar;93(3):403-9
pubmed: 23955074
Nat Rev Drug Discov. 2018 Oct 30;17(11):777
pubmed: 30374183
Biol Blood Marrow Transplant. 2014 May;20(5):684-9
pubmed: 24492141
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Blood. 2021 May 13;137(19):2634-2645
pubmed: 33211842
Leuk Lymphoma. 2021 Sep;62(9):2161-2168
pubmed: 33764240
Bone Marrow Transplant. 2020 Feb;55(2):393-399
pubmed: 31541205
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Int J Cancer. 2020 Jun 1;146(11):2968-2978
pubmed: 31424568
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
Cancer. 2020 Jan 15;126(2):304-310
pubmed: 31626339
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16
pubmed: 19219604
Ann Oncol. 2018 May 1;29(5):1266-1272
pubmed: 29444231
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Clin Cancer Res. 2013 Apr 1;19(7):1660-9
pubmed: 23339126
Lancet Oncol. 2020 Jul;21(7):978-988
pubmed: 32511983
Lancet Haematol. 2020 Jul;7(7):e511-e522
pubmed: 32589977
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
J Clin Oncol. 2013 Jun 10;31(17):2103-9
pubmed: 23650408
Haematologica. 2021 Sep 01;106(9):2417-2426
pubmed: 34196165
Br J Haematol. 2017 Oct;179(1):50-60
pubmed: 28653407
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25
pubmed: 26314773
Blood. 2003 Sep 15;102(6):1989-96
pubmed: 12676776
Indian J Pathol Microbiol. 2017 Jan-Mar;60(1):87-91
pubmed: 28195099
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
Haematologica. 2013 Nov;98(11):1726-31
pubmed: 23753028